Eikon Therapeutics, Inc. (NASDAQ:EIKN) Stock Has Consensus Price Target of $24.67 According to Analysts

Shares of Eikon Therapeutics, Inc. (NASDAQ:EIKN) have received an average rating of “Moderate Buy” from the nine ratings firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $24.67.

Several research firms have commented on EIKN. Mizuho raised Eikon Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 16th. Wedbush dropped their price target on Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating on the stock in a research note on Friday, August 14th. HC Wainwright assumed coverage on shares of Eikon Therapeutics in a research report on Friday, October 16th. They set a “buy” rating and a $23.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Eikon Therapeutics in a research report on Friday, August 21st. Finally, Weiss Ratings upgraded Eikon Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research note on Monday, August 3rd.

Eikon Therapeutics Stock Up 1.0%

Eikon Therapeutics stock opened at $5.90 on Friday. The company has a market capitalization of $319.60 million and a PE ratio of -1.44. Eikon Therapeutics has a 12-month low of $5.01 and a 12-month high of $17.40. The firm’s fifty day moving average is $8.01 and its 200 day moving average is $10.15.

Eikon Therapeutics (NASDAQ:EIKN) last issued its earnings results on Thursday, August 13th. The company reported ($1.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.61) by ($0.02). Sell-side analysts expect that Eikon Therapeutics will post -7.12 EPS for the current fiscal year.

Insider Buying and Selling

In other news, major shareholder Group Iv Gp Lp Column bought 89,200 shares of Eikon Therapeutics stock in a transaction on Thursday, September 3rd. The stock was purchased at an average cost of $11.56 per share, with a total value of $1,031,152.00. Following the purchase, the insider directly owned 89,200 shares of the company’s stock, valued at approximately $1,031,152. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Institutional Investors Weigh In On Eikon Therapeutics

A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. increased its position in shares of Eikon Therapeutics by 29.0% during the second quarter. BlackRock Inc. now owns 4,281,425 shares of the company’s stock worth $55,873,000 after acquiring an additional 962,046 shares in the last quarter. Regents of The University of California bought a new stake in Eikon Therapeutics during the 3rd quarter valued at $5,106,000. State Street Corp purchased a new stake in Eikon Therapeutics in the second quarter valued at approximately $4,621,000. Parkman Healthcare Partners LLC purchased a new stake in shares of Eikon Therapeutics in the 2nd quarter valued at approximately $3,341,000. Finally, Comprehensive Financial Management LLC purchased a new stake in shares of Eikon Therapeutics in the 2nd quarter valued at approximately $1,517,000.

Eikon Therapeutics Company Profile

Eikon Therapeutics is a biotechnology company focused on discovering and developing medicines by combining advanced live-cell imaging with computational and biological research. Its technology platform is designed to observe the behavior of individual proteins in living cells, helping researchers investigate disease mechanisms and identify potential therapeutic targets.

The company applies this platform to drug discovery and development, with an emphasis on oncology and other serious diseases.